Analysts Set Kala Pharmaceuticals Inc (KALA) Price Target at $35.80

Kala Pharmaceuticals Inc (NASDAQ:KALA) has earned a consensus recommendation of “Buy” from the seven analysts that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $35.80.

KALA has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. set a $35.00 price objective on Kala Pharmaceuticals and gave the stock a “buy” rating in a research report on Sunday, November 19th. Wedbush reiterated a “buy” rating and issued a $46.00 price objective on shares of Kala Pharmaceuticals in a research report on Thursday, November 30th. BidaskClub upgraded Kala Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, December 29th. Finally, Wells Fargo & Co reiterated a “buy” rating on shares of Kala Pharmaceuticals in a research report on Friday, January 5th.

In other news, major shareholder Orbimed Advisors Llc purchased 170,338 shares of the stock in a transaction on Wednesday, January 10th. The shares were acquired at an average price of $12.83 per share, for a total transaction of $2,185,436.54. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have acquired 1,108,150 shares of company stock worth $15,772,394 in the last 90 days.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KALA. Victory Capital Management Inc. purchased a new stake in Kala Pharmaceuticals during the third quarter valued at about $12,414,000. Bank of New York Mellon Corp bought a new position in shares of Kala Pharmaceuticals during the third quarter valued at about $540,000. Commonwealth Equity Services Inc bought a new position in shares of Kala Pharmaceuticals during the third quarter valued at about $360,000. EAM Investors LLC bought a new position in shares of Kala Pharmaceuticals during the third quarter valued at about $1,353,000. Finally, American International Group Inc. bought a new position in shares of Kala Pharmaceuticals during the third quarter valued at about $122,000. Institutional investors and hedge funds own 70.82% of the company’s stock.

Shares of Kala Pharmaceuticals (NASDAQ:KALA) traded down $0.36 during mid-day trading on Monday, hitting $14.48. The company had a trading volume of 138,400 shares, compared to its average volume of 454,211. The company has a quick ratio of 11.00, a current ratio of 11.00 and a debt-to-equity ratio of 0.14. Kala Pharmaceuticals has a one year low of $11.81 and a one year high of $26.75. The stock has a market capitalization of $355.29 and a P/E ratio of -8.05.

ILLEGAL ACTIVITY NOTICE: This news story was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/22/analysts-set-kala-pharmaceuticals-inc-kala-price-target-at-35-80.html.

Kala Pharmaceuticals Company Profile

Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.

Analyst Recommendations for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply